CY1106676T1 - Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως - Google Patents

Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως

Info

Publication number
CY1106676T1
CY1106676T1 CY20071100841T CY071100841T CY1106676T1 CY 1106676 T1 CY1106676 T1 CY 1106676T1 CY 20071100841 T CY20071100841 T CY 20071100841T CY 071100841 T CY071100841 T CY 071100841T CY 1106676 T1 CY1106676 T1 CY 1106676T1
Authority
CY
Cyprus
Prior art keywords
nucleic acid
delivery
improving
therapeutic nucleic
recipient
Prior art date
Application number
CY20071100841T
Other languages
English (en)
Inventor
James G. Barsoum
Michael Parr
Stephen E. Fawell
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of CY1106676T1 publication Critical patent/CY1106676T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η εφεύρεση παρέχει μεθόδους και συνθέσεις για την αύξηση της διανομής νουκλεϊνικών οξέων σε ένα δέκτη δια χορηγήσεως ενός νουκλεϊνικού οξέως το οποίο κωδικοποιεί ένα θεραπευτικό νουκλεϊνικό οξύ μαζί με έναν παράγοντα ο οποίος ρυθμίζει τη λειτουργία των κυττάρων Kupffer στο δέκτη.
CY20071100841T 2001-01-22 2007-06-25 Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως CY1106676T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26341601P 2001-01-22 2001-01-22
PCT/US2002/001797 WO2002056918A2 (en) 2001-01-22 2002-01-22 Method of enhancing delivery of a therapeutic nucleic acid

Publications (1)

Publication Number Publication Date
CY1106676T1 true CY1106676T1 (el) 2012-05-23

Family

ID=23001688

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100841T CY1106676T1 (el) 2001-01-22 2007-06-25 Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως

Country Status (13)

Country Link
US (1) US7534424B2 (el)
EP (1) EP1363676B1 (el)
JP (1) JP2005502585A (el)
AT (1) ATE357935T1 (el)
AU (1) AU2002237910B2 (el)
CA (1) CA2435443A1 (el)
CY (1) CY1106676T1 (el)
DE (1) DE60219142T2 (el)
DK (1) DK1363676T3 (el)
ES (1) ES2283524T3 (el)
NZ (1) NZ527645A (el)
PT (1) PT1363676E (el)
WO (1) WO2002056918A2 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
JP4736413B2 (ja) * 2004-12-14 2011-07-27 富士ゼロックス株式会社 生体分子保持物及び生体分子の保存方法
WO2011074564A1 (ja) * 2009-12-15 2011-06-23 タカラバイオ株式会社 アデノウイルスベクターの製造方法
US20140141065A1 (en) * 2012-11-19 2014-05-22 Discovery Genomics, Inc. Method to achieve extended expression of dna infused into liver

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE19525900C1 (de) * 1995-07-15 1996-12-12 Max Planck Gesellschaft Leberspezifischer Adenovirus-Expressionsvektor
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
DE69833264T2 (de) * 1997-08-29 2006-09-28 Biogen Idec Ma Inc., Cambridge Verfahren und zusammensetzungen für die krebstherapie unter verwendung von interferon-beta codierenden genen
AU2001236713A1 (en) * 2000-02-17 2001-08-27 Genzyme Corporation Methods for treatment of lysosomal storage diseases

Also Published As

Publication number Publication date
WO2002056918A2 (en) 2002-07-25
WO2002056918B1 (en) 2004-04-08
AU2002237910B2 (en) 2007-01-25
DK1363676T3 (da) 2007-07-23
AU2002237910C1 (en) 2002-07-30
DE60219142D1 (de) 2007-05-10
US7534424B2 (en) 2009-05-19
US20040086486A1 (en) 2004-05-06
CA2435443A1 (en) 2002-07-25
ATE357935T1 (de) 2007-04-15
EP1363676A2 (en) 2003-11-26
PT1363676E (pt) 2007-06-22
DE60219142T2 (de) 2007-12-13
EP1363676B1 (en) 2007-03-28
JP2005502585A (ja) 2005-01-27
NZ527645A (en) 2008-10-31
WO2002056918A3 (en) 2002-11-14
ES2283524T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
CY1121687T1 (el) Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1115246T1 (el) Τροποποιησεις toy rna, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα μεταφρασης
CY1116149T1 (el) Αντισωματα anti-tnf, συνθεσεις, μεθοδοι και χρησεις αυτων
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
ATE543873T1 (de) Herstellung von 3-hydroxypropionsäure mittels beta-alanine-pyruvat-aminotrransferase
ATE510011T1 (de) Neue pilzproteine und diese codierende nukleinsäuren
CY1116482T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια ογκων, ινωσης, και πνευμονικης κυψελιδικης πρωτεϊνωσης
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
DK0981630T3 (da) Polypeptider med prolyldipeptidylaminopeptidaseaktivitet og nukleinsyrer, der koder for samme
CY1106564T1 (el) Πολυπεπτιδια δυναμενα αποσπασης μιας ανοσιακης αντιδρασης εναντι του καρκινου
CY1106676T1 (el) Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CY1107230T1 (el) Υποκατεστημενες ενωσεις 1-φαιναιθυλοπιπεριδινης, οι οποιες μεταξυ αλλων χρησιμοποιουνται σαν αναλγητικα
CY1110418T1 (el) Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
DE60335497D1 (de) Ergillus-phytasen
GT200300154A (es) Aldehidos de polietilenglicol
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.